FURTHER inFORMATiOn
W. M. Bonner's homepages: http://ccr.cancer.gov/staff/staff. asp?profileid=5814; http://discover.nci.nih.gov/ all linkS are acTive in THe online pDf Molecular oxygen (O 2 ) is required for aerobic metabolism to maintain intracellular bioenergetics and to serve as an electron acceptor in many organic and inorganic reactions. Hypoxia, defined as reduced O 2 levels, occurs in a variety of pathological conditions, including stroke, tissue ischaemia, inflammation and the growth of solid tumours. The beginnings of hypoxia research in tumour biology can be traced back to observations made in the early 20th century by Otto Warburg, who demonstrated that, unlike normal cells, tumour cells favour glycolysis, independent of cellular oxygenation levels (TIMeLINe). He postulated that tumour growth is caused by mitochondrial dysfunction in neoplastic cells, which forces them to generate energy through glycolysis (reviewed in reF. 1) . This hypothesis appears to be incorrect, but a number of other molecular mechanisms promoting 'aerobic glycolysis' have been proposed, including mutations and epigenetic changes in genes encoding tumour suppressors (for example, TP53), activation of oncogenes (such as MYC) and hypoxic adaptations [2] [3] [4] . Ambient air is 21% O 2 (150 mm Hg); however, most mammalian tissues exist at 2%-9% O 2 (on average 40 mm Hg). Hypoxia is usually defined as ≤2% O 2 , and severe hypoxia (or anoxia) is defined as ≤0.02% O 2 . In the decades following Warburg's observation, scientists sought to determine whether hypoxic or anoxic cells could be found in mammalian tumours and how these cells affected radiation therapy (TIMeLINe) . Of great interest to radiation biologists and oncologists, the radioprotective effect of anoxia in normal tissues was demonstrated in the 1940s by Lacassagne and Evans et al., using whole-body anoxia in newborn rodents (reviewed in reF. 5) . If a subset of tumour cells did in fact exist in an environment deprived of O 2 , then they might be responsible for tumour recurrence after radiation. This realization is still fuelling research today, over 60 years later.
Early demonstrations of tumour hypoxia
Before hypoxic cells could be visualized in tumours, their presence was inferred by some astute observations. In 1955, Thomlinson and Gray studied histology sections of human lung tumours and observed cells growing in cords running parallel to vascularized stroma 6 . In large cords, they noted a necrotic core surrounded by a region of viable cells neighbouring a capillary vessel. They proposed that necrosis was due to insufficient supply of O 2 and nutrients to the rapidly expanding tissue. Regardless of cord size, detectable bands of live cancer cells lying between the necrotic core and the surrounding stroma were consistently 170 micrometres in width, which is approximately the calculated distance of O 2 diffusion (145 micrometres). They proposed that the edges of such necrotic cores harbour viable hypoxic tumour cells 6 . Other human tumours, such as cervical and renal carcinomas, exhibited similar histological characteristics, suggesting that this was not unique to the lung (reviewed in reF. 7) . The histological specimens also suggested that tumour cells are exposed to an O 2 gradient decreasing gradually from efficient oxygenation near the stroma to near anoxia bordering the necrotic regions. These varying O 2 concentrations have since been shown to have significantly different effects on cellular processes 8 .
Further evidence for the existence of viable hypoxic tumour cells that may influence tumour responses to radiation was offered by Powers and Tholmach. They irradiated lymphosarcomas in mice breathing either ambient air or hyperbaric O 2 (3 atmospheres of pressure) before transplanting them to a new mouse host. They observed decreased tumour cell survival in tumours transplanted from mice breathing hyperbaric O 2 compared with 21% O 2 , suggesting that certain tumour cells were protected by decreased O 2 conditions but were sensitized by a surplus of O 2 delivered to the host. Moreover, tumours irradiated in dead mice (probably more hypoxic than viable animals breathing room air) were much less sensitive to radiation 9 . Around the same time, churchillDavidson made similarly encouraging observations in cancer patients treated with radiation in combination with hyperbaric O 2 (reF. 10) . Although these results were promising and suggestive of the existence of Abstract | During the past century it has been established that regions within solid tumours experience mild to severe O 2 deprivation owing to aberrant vascular function. these hypoxic regions are associated with altered cellular metabolism, as well as increased resistance to radiation and chemotherapy. As discussed in this timeline, over the past decade work from many laboratories has elucidated the mechanisms by which hypoxia-inducible factors (HiFs) modulate tumour cell metabolism, angiogenesis, growth and metastasis. the central role played by intra-tumoural hypoxia and HiF in these processes has made them attractive therapeutic targets in the treatment of multiple human malignancies. 31 P signals to monitor tumour cell metabolism and sensitizer adducts such as misonidazole 13, 14 that selectively bind hypoxic cells were also used in an attempt to identify hypoxic regions (reviewed in reF. 15 ). However, none of these methods were ideal. Although electrode measurements were certainly the most direct form of O 2 measurement available, some human tumours were not accessible to electrodes and the electrode diameters were too large to allow precise measurements of cellular oxygenation status. Instead, they probably measured average O 2 tensions in tumour sections, which would not accurately reflect the dramatic variations that occur over small distances 16 . cryospectrophotometric measurements readily determine the oxyhaemoglobin saturation of individual erythrocytes in tumour vessels ex vivo, an indirect assessment of tumour oxygenation 12 . 31 P NMR spectroscopy was found to lack sensitivity, and technical difficulties still limited the use of sensitizer adducts 15 . using several of these methods, studies in both the 1980s and early 1990s found lower average O 2 tensions in human tumour tissue than in normal tissue, as predicted by previous work. However, substantial inter-tumour variability was observed, indicating that predictions of tumour oxygenation would be difficult and underscoring the urgent need for more precise and direct O 2 measurement techniques that could be easily used in clinical settings 12 . In the late 1980s, an additional complication was revealed by chaplin et al., using Hoechst 33432. This DNA-binding stain has a short distribution half-life but remains bound to tumour cell DNA, thus labelling cells based on their proximity to the blood supply. coupling this technique with cell sorting and responses to treatment, chaplin differentiated between diffusion-limited, chronic hypoxia and acute hypoxia resulting from transient changes in blood flow through tumour vasculature of larger tumours. cells adjacent to blood vessels may suddenly and intermittently become hypoxic as the vessel becomes momentarily occluded during treatment 17 . These two types of hypoxia may have different effects on treatment responses, a possibility that must be considered in the selection of cancer therapy protocols 18 .
The effects of hypoxia on cancer The major focus of hypoxia research for most of the 20th century was its role in cancer treatment responses. As early as 1909, Schwarz and colleagues noted that normal mammalian cells irradiated under conditions of hypoxia or anoxia were less sensitive to radiation than those irradiated in the presence of O 2 (reF. 21) . At that time, the changes were attributed to blood flow differences, and not to oxygen availability. In 1923, Petry's studies on the effects of oxygen on vegetable seeds were the first to note a correlation between oxygen and radiosensitivity (reviewed in reF. 22 . Subsequently, churchillDavidson published a cytological evaluation of damage in patient tumours after radiation. One half of the tumour was irradiated while patients breathed hyperbaric O 2 at 3 atmospheres pressure, the other half while patients were breathing room air. Significantly more damage was observed in the half irradiated under high O 2 conditions 24 . In 1960, Dewey used human embryo liver cells to show that cells grown in vitro under anoxic conditions exhibited ~2.5-fold greater colony-forming ability after irradiation than cells grown in air 25 . Hewitt and Wilson irradiated mouse leukaemia cells in live mice or 2 minutes after death and observed a sensitivity ratio identical to that observed by Dewey 26 . Several years later, the experiments by Powers and Tholmach described above further confirmed these findings 9 . Numerous other studies followed that evaluated the effects of hypoxia on transplanted or spontaneous tumour regression after irradiation in mice and confirmed earlier experiments (reviewed in reF. 27) . Similarly, hypoxic cells were later found to be more resistant to many commonly used chemotherapeutic agents 28, 29 . However, the 1970s and 1980s witnessed a shift in opinions concerning the importance of hypoxia in clinical responses to cancer treatment. Observed responses, first to hyperbaric O 2 treatment 30 and later to hypoxic cell radiosensitizers 31 , were disappointing. Furthermore, hypoxic tumour cells appeared to reoxygenate in response to fractionated radiation treatment and therefore would have substantially less impact on tumour cell responses after fractionated therapy than after a single radiation dose 32, 33 . Finally, scientists found that intrinsic cellular radiosensitivity alone at low doses could explain the differences in clinical responses observed 34 . Many became sceptical about whether the radiosensitization of hypoxic tumour cells was going to be clinically beneficial.
The following decade witnessed a second shift in conventional wisdom. With the demonstration in the 1980s and 1990s that, like other mammalian tumours, human tumours also contained radioresistant hypoxic cells came the realization that hypoxic cells could be targeted directly with hypoxia-specific cytotoxins. The combination of radiation with a hypoxia-specific cytotoxin would thus have the potential to destroy the entire tumour cell population. Such cytotoxins thus became the focus of intense investigation in the early 1990s 35 . The question of the role of hypoxia in cancer treatment instigated many studies, some of which revealed a number of other crucial effects of hypoxia on tumour progression, as discussed in detail later, including angiogenesis 36 , increased metastatic potential 37, 38 , DNA replication 38, 39 and reduced protein synthesis 40 . Finally, in the decade immediately preceding the discovery of the transcription factor hypoxia-inducible factor (HIF), the expression of a number of genes was determined to be stimulated by O 2 deprivation. The earliest to be identified were glucose-regulated proteins (GRPs) and O 2 -regulated proteins (ORPs) 40, 41 . One ORP was later identified as haem oxygenase 42 , and two others were revealed to be the same as two GRPs 41, 43 . Other genes induced by hypoxia include those regulating haematopoiesis and the vasculature (vascular endothelial growth factor (VEGFA) 44 , interleukin 1A (IL1A) 45 , endothelin 1 (reF. 46 ), platelet-derived growth factor B (PDGFB) 47 , and erythropoietin (EPO) 48 ), glycolysis 49 , metastasis (cathepsin L 50 ) and DNA damage responses (GADD45A and GADD153 (also known as DDIT3) 51 ). How the cell sensed O 2 deprivation and how gene transcription was regulated by hypoxia were completely open questions until the discovery of HIFs in the 1990s and further elucidation of HIFaindependent effects of hypoxia on cellular processes over the following decades (see below).
identification of hypoxia-inducible factors HIFs are heterodimeric transcription factors consisting of an a and a β subunit 52 . Systematic characterization of EPO by multiple groups led to the identification of a cis-acting hypoxia response element (HRE; 5′-TAcGTGcT-3′) in the 3′-flanking region of this locus that confers O 2 regulation of EPO expression [53] [54] [55] [56] . HIF1 was subsequently described by Gregg Semenza and Guang Wang in 1992 as a nuclear factor that is induced by hypoxia, binds to the EPO HRE and promotes transcriptional activation of EPO in O 2 -starved cells 57, 58 . The HIF1 binding site within the EPO HRE was used for purification of HIF through DNA affinity chromatography and the cloning of cDNAs encoding the HIF1a and HIF1β subunits in 1995 (reF. 52) . This demonstrated that both subunits are members of the basic helix-loop-helix polypeptide family that contain a PAS domain, which was initially characterized in the Drosophila melanogaster proteins PER and SIM and the mammalian protein aryl hydrocarbon nuclear translocator (ARNT). Whereas HIF1a was a novel protein, HIF1β was in fact identical to ARNT. HIF1a and HIF1 DNA-binding activity were rapidly induced by hypoxia (1% O 2 ), and quickly decayed upon reoxygenation of cells to ambient O 2 levels (21%). Finally, HIF1a protein levels were shown to increase exponentially as HeLa cells were exposed to decreasing O 2 concentrations (from 6% to 0.5%), with a half-maximal response between 1.5% and 2% O 2 (reF. 59) .
The HIFa-HIFβ dimer binds to HREs (5′-G/AcGTG-3′) that are associated with numerous transcriptional target genes that are crucial to systemic hypoxia responses, such as angiogenesis and erythropoiesis, and cellular hypoxia responses involving metabolism, proliferation, motility and autophagy (FIG. 1) . In fact, hypoxia may be one of the most potent inducers of autophagy, the process by which cellular components are degraded and recycled to restore ATP levels 60 . HIF target genes influence 
. In mammals, three genes have been shown to encode HIFa subunits that appear to be similarly regulated by O 2 availability. Of the three HIFa proteins, HIF1a and HIF2a (also known as endothelial PAS domain protein 1 (EPAS1)) have been the most extensively characterized 61 . In addition to being identified first, HIF1a is expressed ubiquitously, whereas HIF2a and HIF3a are found in a subset of tissues. HIF2a also binds to HREs and upregulates gene expression but is restricted to vascular endothelium, liver parenchyma, lung type II pneumocytes and kidney epithelial cells [62] [63] [64] . By contrast, HIF3a (also known as inhibitory PAS domain protein (IPAS)) acts as a dominant negative regulator of HIF1a-and HIF2a-mediated transcription and is found at high levels in the thymus, cerebellar Purkinje cells and the corneal epithelium of the eye 65, 66 . unlike the HIFa proteins, HIF1β is constitutively expressed and insensitive to changes in O 2 levels. Whereas HIFΑ mRNA levels change in response to hypoxia in select cell types, HIF regulation is primarily based on post-translational modification and protein stability (FIG. 2) .
It is important to note that although the HIFs are crucial mediators of the transcriptional response to hypoxia, a number of HIF-independent pathways also respond to changes in O 2 tension (FIG. 3) . These responses allow cells to acutely adapt to the energetic demands of decreased O 2 availability by limiting energy-consuming processes such as protein synthesis. Our understanding of the importance and regulation of these pathways is only beginning to emerge. (FIG. 3) ? Huang et al. determined that HIFa subunit stability is largely regulated through a region of 200 amino acids that is referred to as the oxygendependent degradation domain (ODD) 67 . Direct analysis of the HIF1a protein revealed that it is ubiquitylated and degraded by the 26S proteasome in O 2 -replete cells [67] [68] [69] . P. Ratcliffe, P. Maxwell and colleagues demonstrated in 1999 that renal carcinoma cells lacking the von Hippel-Lindau tumour suppressor protein (vHL) constitutively express both HIF1a and HIF2a as well as multiple HIF target genes 70 . Hypoxic regulation of HIF could be restored upon reintroduction of plasmids encoding the vHL polypeptide. vHL is the substrate recognition component of a ubiquitin protein ligase complex that includes elongin B (also known as TcEB2), elongin c (TcEB1), cuL2 and ring box protein 1 (RBX1) (reFs 70-74). W. Kaelin, N. Pavletich and co-workers determined that this complex is related to the SKP1-cuL1-F-box (ScF) family of ubiquitin protein ligases that catalyse the transfer of ubiquitin from ubiquitin-conjugating enzymes to specific lysine residues of their substrates 75 . Biochemical studies performed by the research groups of Ratcliffe, Kaelin and F. Lee indicated that HIFa interaction with vHL requires the hydroxylation of proline residue 564 (within the human HIF1a ODD) by an enzymatic activity that is dependent on O 2 , 2-oxoglutarate and iron, and is reminiscent of procollagen prolyl hydroxylases [76] [77] [78] . A family of three HIF-specific prolyl hydroxylases was subsequently identified by character izing candidate genes that encode 2-oxoglutarate-dependent dioxygenases 147, 148 . A point mutation in VHL leading to Chuvash polycythaemia preferentially stabilizes HIF2a 149 . cardiovascular disease Cardiac ischaemia is a significant source of patient mortality. The adaptive responses mediated by the HIFs are important for protecting ischaemic tissues from injury, and activating the HIF pathway selectively in these tissues could provide an important therapeutic intervention [150] [151] [152] . pulmonary hypertension Both HIF1a and HIF2a regulate vascular remodelling and the development of pulmonary hypertension in response to chronic hypoxia 153, 154 . inflammation Hypoxia is commonly observed in inflammatory states, and HIF1a can have protective as well as pro-inflammatory effects. Macrophage-specific deletion of HIF1a revealed that it had an important role in mediating innate immune responses 155 . Moreover, deletion of HIF1a in colonic epithelium revealed a protective function in drug-induced colitis 156 . (FIG. 2) . The ability of HIFa to interact with co-activators such as p300-cREBBP (cREB-binding protein) exclusively under hypoxic conditions is also regulated by hydroxylation, in this case that of a carboxy-terminal asparagine residue by factor inhibiting HIF1 (FIH1, also known as HIF1AN) [82] [83] [84] [85] . FIH1 is also an iron-and 2-oxoglutarate-dependent dioxygenase that probably fine-tunes the regulation of HIF by O 2 availability.
HiFs and cellular O 2 sensing
How the HIF pathway senses changes in O 2 concentration has been intensively studied since the cloning of the HIF1a and HIF1β subunits in 1995. Although much has been elucidated concerning O 2 sensing by metazoans, key questions remain, such as how do HIF-independent pathways perceive changes in O 2 availability
The role of HiFs in cancer
On the basis of the analysis of human cancer biopsy samples and experimental animal models, it has become increasingly clear that HIFs have a crucial role in cancer progression [86] [87] [88] . Immunohistochemical techniques have demonstrated that HIF1a is overexpressed in a broad range of human malignancies 87 . Furthermore, HIF1a accumulation has been associated with poor patient survival in early-stage cervical cancer 89 , breast cancer 90, 91 , oligodendroglioma 92 , ovarian cancer 93 , endometrial cancer 94 and oropharyngeal squamous cell carcinoma 95 .
Significant associations between HIF2a
overexpression and increased patient mortality have been reported for other diseases, including non-small-cell lung cancer 96 , neuroblastoma 97 , astrocytoma 98 , and head and neck squamous cell carcinoma 99 . Interestingly, HIF1a overexpression was associated with decreased patient mortality for head and neck cancer 100 and non-smallcell lung cancer 101 , suggesting that these two HIFa subunits can have opposing effects on disease progression depending on tumour type. Similarly, HIF1a expression gradually decreases whereas HIF2a expression increases as renal carcinomas develop in patients with vHL disease, the cancer susceptibility syndrome that is associated with germline VHL mutations 102, 103 . An association between HIF3a expression and patient prognosis has not been examined.
Numerous experiments involving subcutaneous injection of murine and human cancer cell lines into immunodeficient mice have supported the notion that HIFs figure prominently in tumour growth. The first experiment was performed by the Ratcliffe group using ARNT-deficient mouse hepatoma cells 104 . compared with tumours generated from wild-type cells, mutant tumours grew more slowly and exhibited decreased angiogenesis. R. Johnson and coworkers demonstrated that immortalized and transformed Hif1a -/-mouse embryo fibroblasts also produced smaller tumours in subcutaneous models 105 . D. Livingston, A. Kung and colleagues disrupted HIF transcriptional activity by introducing c-terminal HIF1a peptides into human breast and colon cancer cells, resulting in decreased tumour growth in nude mice 106 . This peptide functions by inhibiting the ability of HIF1a to interact with the cREBBP and p300 cofactors. consistent with vHL patient sample analysis (see above), inhibiting HIF1a in renal carcinoma cells results in increased xenograft tumour mass, whereas HIF2a inhibition results in decreased tumour growth in nude recipients 103 . Ectopic expression of HIF3a in hepatoma cells decreases tumour growth and angiogenesis in a subcutaneous tumour model, consistent with the dominant negative function of HIF3a 66 . Finally, downregulating HIF2a through RNA interference resulted in decreased subcutaneous neuroblastoma growth 97 . The studies in renal carcinoma, which were the first to directly demonstrate that HIF1a and HIF2a could have opposing effects on tumour growth, spurred a new interest in understanding the molecular differences between the a subunits. These observations also demonstrated that the relative contributions of the a subunits to tumour growth versus suppression are likely to be tissue-specific.
Although the injection of human cancer cells into immunocompromised mice has aided our understanding of the role of HIFs in cancer, this approach exclusively evaluates the terminal stages of malignancy. It fails to investigate the processes of tumour initiation, progression and metastasis over a prolonged period of disease. The use of conditional alleles of murine Hif1a and Hif2a in spontaneous mouse models of cancer should greatly advance the field. Recently, Liao et al. have demonstrated a pivotal role for HIF1a in pulmonary metastasis using a transgenic model of breast cancer 107 . Here, HIF1a was conditionally ablated in the mammary epithelium of mice expressing the polyoma middle T oncoprotein in mammary glands. HIF1a deficiency resulted in delayed tumour onset, reduced tumour growth and somewhat fewer tumour blood vessels. However, the number of metastases to the lung was significantly decreased. These results indicate that HIF1a has an unexpected role in promoting metastatic potential. A role for HIF1a in promoting breast cancer metastasis was also described by Hiraga et al. 108 . validating the observations that have been made in mouse models through expression profiling and immunohistochemistry of patient samples will also be an important tool to extend experimental findings to the clinic 109 . Increased HIF1a expression can be caused by a variety of genetic alterations that Figure 3 | Hypoxia regulates other crucial pathways that affect tumour progression in a Hifindependent fashion. A schematic diagram of signalling pathways that regulate mrNA translation is shown. these include the mtOr pathway and the integrated stress response. Hypoxia influences the activities of AMP-activated protein kinase (AMPK) and reDD1, which act upstream to inhibit mtOr kinase activity, resulting in a decrease in cap-dependent translation. Hypoxia also inhibits the endoplasmic reticulum resident kinase PerK (also known as eukaryotic translation initiation factor 2-a (eiF2a) kinase 3 (eiF2AK3)), which phosphorylates eiF2a, resulting in global protein synthesis inhibition. Although HiFs contribute to mtOr regulation through the induction of reDD1 during chronic hypoxia, all of these pathways can be regulated by O 2 deprivation in a HiF-independent manner. Although the mechanisms for regulation of mtOr and PerK by changes in O 2 remain unclear, they are important additional therapeutic targets. 4eBP1, eiF4e binding protein 1; mtOrc1, mtOr complex 1; tSc2, tuberous sclerosis 2. . More recent studies have supported these initial observations, although some controversy concerning interactions between the HIF1a and p53 pathways remains to this day.
HIFs also affect the MYc pathway: whereas HIF1a opposes MYc 112 , a potent regulator of proliferation and anabolic metabolism, HIF2a promotes MYc activity 113 . These observations describe crosstalk between responses to changes in O 2 availability and a key transcription factor regulating cell growth 114 . Because MYc is commonly deregulated in cancer, this is also an important interaction to consider when developing anticancer therapies.
Therapeutic implications
As described previously, early work on the role of O 2 levels in cancer centred on the observation that poorly perfused tissues are more resistant to radiation 115 . It was later that Gray made the direct connection between tissue oxygenation and tumour cell radioresistance, a principle known as the O 2 enhancement effect 5 . O 2 was thought to act as a direct radiosensitizer, increasing damage to DNA through the formation of free radicals. Indeed, experiments conducted by R. Hodgkiss and colleagues in the late 1980s demonstrated that the oxygen effect required O 2 to be present at the exact time of radiation, leading to the oxygen fixation hypothesis 116 
. The relative contributions of cellular responses to hypoxia and the direct effects of free radicals to hypoxic radioresistance are still being deciphered.
Early attempts to exploit the oxygen effect for therapeutic benefit focused on interventions to increase tumour oxygenation during radiation. Hyperbaric O 2 , red blood cell transfusions and erythropoietin administration were all attempted as methods to increase tumour oxygenation. However, these approaches did not gain widespread use owing to conflicting reports of their efficacy in clinical trials 117 . In the 1970s, nitroimidazole derivatives, which act as molecular mimics for O 2 , were tested in conjunction with radiation. Despite initial promise, clinical trials with nitroimidazoles demonstrated limited benefit, in part owing to dose-limiting toxicities 118 . As an alternative to increasing tumour oxygenation, more recent strategies have attempted to take advantage of hypoxia to selectively kill tumour cells. Tirapazamine, described over 20 years ago, is a prototypical example of a hypoxia-activated prodrug 119 . Tirapazamine is specifically reduced in hypoxic cells, forming radical species that poison topoisomerase II and lead to DNA double-strand breaks 120 . clinical trials with this agent in combination with radiation or chemotherapy have demonstrated benefits in patients with lung cancer or head and neck cancer 121, 122 . In addition to the direct role of O 2 in generating radiation-induced DNA damage, the biological effects of hypoxia on tumour cells can also modulate their response to therapy. This was first demonstrated several decades ago in experiments showing that the duration of hypoxia influenced radiation sensitivity 123 . collectively, hypoxia modulates multiple pathways that contribute to radiation and chemotherapy resistance. Hypoxia exerts a selective pressure on cells for loss of p53, a key mediator of apoptosis, and upregulates the expression of the multidrug resistance gene (MDR1, also known as ABCB1), leading to efflux of chemotherapeutic drugs [124] [125] [126] . Hypoxia has also been shown to contribute to increased mutagenesis rates and metastasis [127] [128] [129] [130] . Lysyl oxidase, MET and c-X-c chemokine receptor 4 (CXCR4) are examples of genes directly regulated by hypoxia that have important roles in metastasis and could serve as druggable targets.
Given the impact of hypoxia on therapeutic efficacy and patient prognosis, the ability to measure and image hypoxia in tumours has garnered significant attention. [132] [133] [134] . Nitroimidazoles are reduced under hypoxic conditions, forming stable adducts in the cell that can be detected by the positron-emission tomography scanner. Although many of these approaches are currently being investigated for their ability to predict treatment response, they still have not attained routine use in the clinic.
The cloning of HIF, understanding of the pathways that regulate it and identification of downstream HIF targets have produced numerous molecular targets for therapeutic intervention. Targeting the HIF pathway has generated significant attention because of the potential to selectively target hypoxic tumour cells and the part that hypoxia plays in key tumorigenic processes such as metastasis, angiogenesis and metabolism. Owing to the difficulty in directly targeting transcription factors, the 136 . In addition to the hypoxia-regulated vHL-dependent HIF degradation pathway, HIF is degraded through interaction with receptor of activated protein kinase c (RAcK1, also known as GNB2L1) 137 . RAcK1 competes with heat shock protein 90 (HSP90) for binding to HIF1a, and HSP90 inhibitors have been shown to promote HIF degradation. Targeting of the interaction between HIF and the transcriptional co-activator p300 has also been demonstrated to inhibit HIF target gene expression and impair tumour growth 106, 138 . Numerous other small molecules, including topoisomerase inhibitors, microtubule destabilizers and histone deacetylase inhibitors, inhibit HIF1a accumulation, although the mechanism for these effects is not yet clear 139 .
Finally, drugs against several key HIF transcriptional targets have been developed and approved for clinical use. chief among these is bevacizumab (Avastin, Genentech), a monoclonal antibody against vEGFA, which is a key endothelial growth factor involved in tumour angiogenesis 140 . Bevacizumab is now commonly used for the treatment of metastatic colorectal cancer 141 . vEGFA activity can also be inhibited by vEGFA receptor tyrosine kinase inhibitors such as sorafenib (Nexavar, Bayer), which has shown clinical benefit in renal and hepatocellular carcinoma 142 . The therapeutic effects of anti-vEGFA therapy appear to involve several mechanisms, often depending on the tumour type and chemotherapy regimen. These effects include inhibition of angiogenesis, endothelial cell apoptosis and vessel normalization 143 . Additionally, epidermal growth factor receptor inhibitors such as gefitinib (Iressa, AstraZeneca) have seen some success in the treatment of lung cancer 144, 145 . Hypoxia research in the past century has provided significant advancement in our understanding of the molecular pathways by which O 2 tension influences the properties of tumours, from proliferation and angiogenesis to radiation and chemotherapy resistance. current studies are focused on extending the observations made in vitro to more physiological contexts. The cloning of the HIFs has provided a genetic tool that, when coupled with established mouse models of cancer, will help to clarify HIF-dependent effects on disease progression. Accordingly, studies in which one or both of the HIFa subunits are conditionally deleted are now underway and will allow us to determine the tissue-and stage-specific effects of these factors on tumour progression. Mouse models will also be a useful platform to test newly identified therapies that target the HIF pathway for the treatment of cancer. The recent identification of a number of hypoxia-regulated microRNAs provides another mechanism by which O 2 levels can influence gene expression. A number of these microRNAs are highly expressed in tumours and their predicted targets (for example, BID (BH3-interacting domain death agonist), vEGFA and cyclin D2) have roles in apoptosis, angiogenesis and proliferation. In future studies it will be important to identify the targets of these microRNAs to understand their role in tumorigenesis 146 . Nearly a century after Warburg's initial observation of aerobic glycolysis in tumours, the unique metabolism of cancer cells will be important to re-examine. Specifically, the crosstalk between the HIF pathway and deregulated oncogene and tumour suppressor function in driving metabolic changes will be an important area of study. collectively, these observations will be crucial for the successful development of novel imaging and treatment modalities, with the promise of improving the targeted therapy of cancer and overcoming the therapeutic resistance induced by hypoxia.
Nearly a century after Warburg's initial observation of aerobic glycolysis in tumours, the unique metabolism of cancer cells will be important to re-examine.
